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The RYR2-Encoded Ryanodine Receptor/Calcium
Release Channel in Patients Diagnosed Previously
With Either Catecholaminergic Polymorphic
Ventricular Tachycardia or Genotype Negative,
Exercise-Induced Long QT Syndrome
A Comprehensive Open Reading Frame Mutational Analysis
Argelia Medeiros-Domingo, MD, PHD,* Zahurul A. Bhuiyan, MD, PHD,§ David J. Tester, BS,*
Nynke Hofman, MSC,§ Hennie Bikker, PHD,§ J. Peter van Tintelen, MD, PHD,¶
Marcel M. A. M. Mannens, PHD,§ Arthur A. M. Wilde, MD, PHD,§ Michael J. Ackerman, MD, PHD*†‡
Rochester, Minnesota; and Amsterdam and Groningen, the Netherlands
Objectives This study was undertaken to determine the spectrum and prevalence of mutations in the RYR2-encoded car-
diac ryanodine receptor in cases with exertional syncope and normal corrected QT interval (QTc).
Background Mutations in RYR2 cause type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1), a cardiac chan-
nelopathy with increased propensity for lethal ventricular dysrhythmias. Most RYR2mutational analyses target 3 ca-
nonical domains encoded by 40% of the translated exons. The extent of CPVT1-associated mutations localizing out-
side of these domains remains unknown as RYR2 has not been examined comprehensively in most patient cohorts.
Methods Mutational analysis of all RYR2 exons was performed using polymerase chain reaction, high-performance liquid
chromatography, and deoxyribonucleic acid sequencing on 155 unrelated patients (49% females, 96% Cauca-
sian, age at diagnosis 20  15 years, mean QTc 428  29 ms), with either clinical diagnosis of CPVT (n  110)
or an initial diagnosis of exercise-induced long QT syndrome but with QTc 480 ms and a subsequent negative
long QT syndrome genetic test (n  45).
Results Sixty-three (34 novel) possible CPVT1-associated mutations, absent in 400 reference alleles, were detected in
73 unrelated patients (47%). Thirteen new mutation-containing exons were identified. Two-thirds of the CPVT1-
positive patients had mutations that localized to 1 of 16 exons.
Conclusions Possible CPVT1 mutations in RYR2 were identified in nearly one-half of this cohort; 45 of the 105 translated ex-
ons are now known to host possible mutations. Considering that 65% of CPVT1-positive cases would be discov-
ered by selective analysis of 16 exons, a tiered targeting strategy for CPVT genetic testing should be
considered. (J Am Coll Cardiol 2009;54:2065–74) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.022i
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RYR2 Screening in CPVT or Gene Negative LQTS November 24, 2009:2065–74years, CPVT is one of the most
malignant cardiac channelopathies
expressed predominately in young
patients with otherwise structurally
normal hearts (2). While the resting
12-lead electrocardiogram is typi-
cally normal, the hallmark arrhyth-
mia, bidirectional VT, may be
present during exercise stress testing
and has been considered pathogno-
monic for CPVT (1,3).
CPVT stems from an alter-
ation of intracellular calcium
handling involving the critical
alcium-induced calcium release mechanism of myocardial
ells. At the molecular level, gain of function mutations in
he cardiac ryanodine receptor encoded by RYR2 account
or at least 50% of CPVT cases and are annotated as type 1
PVT (CPVT1) (3). Mutations in CASQ2-encoded calse-
uestrin are responsible for the very rare, autosomal reces-
ive form known as type 2 CPVT (CPVT2) (2,4).
The cardiac ryanodine receptor (RyR2), encoded by the
05-exon–containing RYR2 gene, is one of the largest ion
hannel proteins, comprising 4,967 amino acids; it localizes
o the sarcoplasmic reticulum, and controls intracellular
alcium release and cardiac contraction. Since the sentinel
iscovery of a CPVT-causing RYR2 mutation (5), a cluster
istribution involving 3 discrete protein regions has been
eported. On the basis of a potential physiological role for
hese “hot spots,” these regions have been termed “domains”
, II, and III (Fig. 1) (6,7). Similar mutation clustering is
bserved in the RYR1 gene, which encodes the skeletal
uscle RyR1 and is linked to malignant hyperthermia and
entral core disease (8–10). However, because the majority
f CPVT cases have not undergone the entire RYR2 scan,
he prevalence of mutations residing outside these 3 canon-
cal domains (i.e., 61 exons that encode for 2,570 amino
cids) remains unknown.
Currently, among research laboratories and clinical diag-
ostic laboratories, there is no consensus or clear definition
Abbreviations
and Acronyms
CPVT  catecholaminergic
polymorphic ventricular
tachycardia
DNA  deoxyribonucleic
acid
LQTS  long QT syndrome
QTc  corrected QT
interval
RyR2  cardiac ryanodine
receptor
Figure 1 Mutation Clustering in the RyR2
Mutations clustered in the cardiac ryanodine receptor (RyR2) are distributed in
3 “hot-spot” regions, called domains I (N-terminal), II (central), and III (channel
region). AA  amino acid number estimated for each domain. Adapted from
George et al. (7) and Yano et al. (6).if the “RYR2 targeted scan,” resulting in an enormous
iscrepancy in the number of exons studied by each research
roup or commercial company. This situation has an im-
ortant impact in “gene-negative” definition, genotype-
henotype correlation, and patient quality of care. In the
resent study, we sought to determine the prevalence of
utations throughout RYR2’s entire open reading frame in
large cohort of unrelated cases referred to 2 different
nstitutions for exertional syncope and, using a combined
nalysis of the previous reported mutations and the novel
utations found in this cohort, we propose a novel, targeted
genetic approach” for CPVT1 genetic testing.
ethods
tudy participants. We studied a cohort of 155 unrelated
atients referred to either the Windland Smith Rice Sudden
eath Genomics Laboratory at Mayo Clinic, Rochester,
innesota, or the Department of Clinical Genetics, Aca-
emic Medical Center, University of Amsterdam, the Neth-
rlands, for genetic testing between August 2001 and June
008. A clinical diagnosis of CPVT was rendered in 110
atients by either the authors (M.J.A., A.A.M.W.) or the
eferring physician. Of these patients, 78 were classified as
strong CPVT phenotype” because of exertional syncope
lus documentation of bidirectional or polymorphic ventric-
lar tachycardia, and 32 were classified as “possible CPVT
henotype” on the basis of presence of exertional syncope
nd stress test induced ventricular ectopy but not bidirec-
ional or polymorphic ventricular tachycardia. In addition,
5 cases were referred as “possible/atypical long QT syn-
rome” (LQTS) because of exertional syncope and cor-
ected QT interval (QTc) values 480 ms. All 45 were
enotype negative for the 12 known LQTS-susceptibility
enes.
After receipt of written consent for this protocol ap-
roved by the Mayo Foundation Institutional Review Board
nd Amsterdam Academic Medical Center Medical Ethical
ommittee, genomic deoxyribonucleic acid (DNA) was
xtracted from peripheral blood lymphocytes using the
urgene DNA extraction kit (Gentra, Minneapolis, Min-
esota). In cases with suspected mosaicism, additional
NA from saliva was isolated using the ORAgene kit
DNA Genotek, Ottawa, Ontario, Canada), and DNA
rom skin fibroblasts and hair-roots was isolated using the
IAamp DNA minikit (Qiagen, Valencia, California).
utational analysis. Comprehensive open reading frame/
plice site mutational analysis of all 105 RYR2 exons was
erformed using polymerase chain reaction, denaturing
igh-performance liquid chromatography, and DNA se-
uencing as described previously (11). The flanking primers
sed for polymerase chain reaction were published previ-
usly or designed with Oligo software (Molecular Biology
nsights, Cascade, Colorado) and are available on request.
e also searched for large genomic rearrangements affect-
ng exon 3, as reported previously (12).
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November 24, 2009:2065–74 RYR2 Screening in CPVT or Gene Negative LQTSAll putative pathogenic variants must have been absent in
00 reference alleles (100 healthy Caucasian and 100
ealthy black) obtained from the Human Genetic Cell
epository sponsored by the National Institute of General
edical Sciences and the Coriell Institute for Medical
esearch (Camden, New Jersey) to be considered as poten-
ially disease related.
tatistical analysis. We used the JMP Statistical Software
version 6.0, SAS Institute, Cary, North Carolina). All
ontinuous variables are reported as mean  SD. Differ-
nces between continuous variables were evaluated using
npaired Student t tests, and nominal variables were ana-
yzed using chi-square analysis. Statistical significance was
onsidered at p  0.05.
esults
he demographic characteristics of the 155 unrelated pa-
ients are shown in Table 1; 96% were Caucasians, 49%
ere females, age at symptoms was 20  15 years, and
verage QTc was 428  29 ms. The mean age of onset of
ymptoms was significantly lower in RYR2 mutation-
ositive subjects compared with subjects who had a negative
enetic test (16.7  12.3 years vs. 23.8  16.6 years,
espectively; p  0.004).
Overall, 77 (63 unique, 34 novel) putative disease-causing
utations were identified in 73 cases (47%) (Table 2, Fig. 2)
1–3,5,6,12,14,24,26–49). Forty-one of 73 (56%) mutation-
ositive cases were females. Putative mutations were absent in
00 reference alleles, and most of the mutated residues exhibit
igh conservation across species (Supplemental Table). The
ield of the genetic test was significantly higher among the 78
ases classified clinically as “strong CPVT phenotype” com-
ared with the 32 cases diagnosed as “possible CPVT pheno-
ype” (60% vs. 37.5%, p  0.04). Notably, nearly one-third of
he 45 “gene negative LQTS” cases had a rare missense
utation in RYR2 (Table 1, Fig. 3). Four of the 73 RYR2
utation-positive cases hosted multiple mutations (5.5%). As
xpected, we observed a mutation clustering distribution across
YR2; nevertheless, 10 mutations found in 11 cases resided
utside the 3 canonical domains, specifically, between domains
and II; 8 of them exhibited a strong CPVT phenotype. Three
arge genomic rearrangements comprising exon 3 were de-
emographic Characteristics of the CohortTable 1 Demographic Characteristics of the Cohort
CPVT
Strong
Phenotype
CPVT
Possible
Phenotype
Gene
Negative
LQTS Total
n 78 32 45 155
Age, yrs 20 15 20 16 22 14 20 15
QTc, ms 415 26 434 30 434 27 427 29
Percent female 47 44 57 49
RYR2 positives 47 (60.2) 12 (37.5) 14 (31.1) 73 (47.1)
alues are n (%) or mean  SD unless otherwise indicated.(
CPVT  catecholaminergic polymorphic ventricular tachycardia; LQTS  long QT syndrome;
Tc  corrected QT interval.ected in 3 unrelated cases involving a 3.6 kb deletion in 1 and
1.1 kb deletion in 2 cases.
One proband had a maternally inherited Y4149S (ty-
osine, Y, at position 4149 mutated to serine, S) missense
utation. Although the proband’s mother was asymptom-
tic and had an unremarkable exercise electrocardiogram,
ermline mosaicism was suspected clinically because more
han 1 offspring was affected. Accordingly, Y4149S mosa-
cism was detected in her, being highest in the hair-roots
25%), and less in leukocytes (20%) and in fibroblasts
nd buccal epithelium (15% to 18%).
Twelve nonsynonymous single nucleotide polymorphisms
6 novel) were also identified; 7 of them were seen only in
ontrols, and 5 were seen in cases and controls (Table 2).
our novel polymorphisms localized between domains I and
I. The most common polymorphism was Q2958R with a
eterozygous prevalence of 34% in Caucasians and 10% in
frican Americans, followed by G1886S with a prevalence
f 20% (African Americans) and 9% (Caucasians). V377M
as found only in African Americans with a prevalence of
%. Finally, Y2156C, E2183V, M2389L, V4010M,
4282V, and G4315E are rare variants observed only once
n different control subjects. Thus, within the exons hosting
utative CPVT1-associated mutations, the background
revalence of rare amino acid substitutions among the 200
pparently healthy volunteers was 3% (3 of 100 Caucasians
nd 3 of 100 African Americans) (Table 2).
We evaluated the number of mutations in each exon
eported to date in the literature (Table 2), excluding exons
ontaining only polymorphisms. As such, 128 unique mu-
ations were analyzed, including those found within this
ohort. Sixteen exons hosted 3 distinct CPVT1-
ssociated mutations, 13 exons had at least 2 mutations
eported, and an additional 16 exons have had, so far, only
single mutation reported (Fig. 4). This mutation cluster-
ng phenomena might facilitate a tiered strategy that may
ield a more cost-effective approach for CPVT genetic
esting. If we consider that the average charge for the
urrent RYR2 commercial tests available on the market is
$0.40 per coding nucleotide (50,51), the estimated
harge for the entire RYR2 coding region scan would be
$6,000 per patient, meaning that the commercial
harge to analyze this 155-patient cohort in its entirety
ould have approached U.S. $1 million. In comparison,
he total charge to scan only the 45 mutation-hosting
xons that have been reported to date would be 50%
ess. Further, a reflex tiered strategy would reduce the
ost significantly. As modeled here, using a 3-tiered reflex
enetic test strategy, based on Figure 4, the genetic scan
f the first tier of exons in our cohort would cost
190,960 ($1,200 per case) and would detect nearly
wo-thirds of those CPVT cases that are due to muta-
ions in RYR2. The charge to reflex to the second tier
enetic scan would add $1,000 per case and combined,
early 90% of the RYR2-mutation positive cases
CPVT1) would be identified. Reflexing to the third tier
C2068 Medeiros-Domingo et al. JACC Vol. 54, No. 22, 2009
RYR2 Screening in CPVT or Gene Negative LQTS November 24, 2009:2065–74ompendium of RYR2 Mutations and Polymorphisms Reported to DateTable 2 Compendium of RYR2 Mutations and Polymorphisms Reported to Date
Patient
#
Mutation
Number
(Fig. 1) Exon Base Position
Amino Acid
Change Location
Cases Hosting
Variant
(n  155)
AA Hosting
Variant
(n  100)
CC Hosting
Variant
(n  100)
First Author
(Ref. #)
1 1 3 1.1kb deletion* Exon 3 del NT 2 Bhuiyan (12)
2 2 3 3.6kb deletion* Exon 3 del NT 1 Novel
3 3 3 184 CT L62F NT 1 Novel
4 3 230 CT A77V NT d’Amati (27)
5 4 3 241 AC M81L NT 1 Novel
6 5 8 493 CT P164S NT 1 Choi (28)
7 8 506 GA R169Q NT Hsueh (29)
8 6 8 527 GA R176Q NT 1 Tiso (24)
9 7 8 556 GA V186M NT 1 Tiso (24)
10 8 8 567 AT E189D NT 1 Davis (30)
11 10 6337 GA H240R NT Tester (31)
12 9 10 727 GA E243K NT 1 Novel
13 10 12 985 TC F329L NT 1 Novel
14 11 12 994CT R332W NT 1 Novel
15 12 13 1072 GA G357S NT 1 Novel
16 13 13 1129 GA V377M NT 3 Novel
17 14 1240 CT R414C NT Tester (32)
18 14 14 1241 GT R414L NT 1 Choi (28)
19 15 14 1244 CG T415R NT 1 Novel
20 14 1255 AT I419F NT Choi (28)
21 16 14 1258 CT R420W NT 3 Bauce (33)
22 17 14 1259 GA R420Q NT 2 Novel
23 15 1298 TC L433P NT Tiso (24)
24 18 15 1396 CG P466A NT 1 Tester (14)
25 19 16 1519 GA V507I NT 5 4 Novel
26 20 17 1646 CT A549V NT 1 Novel
27 19 Not reported S616L CL Marjamaa (21)
28 21 21 2216 GA R739H CL 1 Novel
29 22 26 3038 GA R1013Q CL 1 Novel
30 27 Not reported R1051P CL Marjamaa (21)
31 23 28 3320 CT T1107M CL 1 Novel
32 24 28 3407 CT A1136V CL 3 2 Novel
33 25 37 5170 GA E1724K CL 2 Postma (34)
34 26 37 5509 GA E1837K CL 1 Novel
35 27 37 5654 GA G1885E CL 2 6 Milting (26)
36 28 37 5656 GA G1886S CL 11 20 9 Milting (26)
37 29 40 6137 AG E2045G CL 1 Novel
38 41 6337 GA V2113M CL 1 Tester (31)
39 41 Not reported G2145R CL Marjamaa (35)
40 30 42 6467 AG Y2156C CL 1 Novel
41 31 42 6504 CG H2168Q CL 2 Novel
42 32 42 6548 AT E2183V CL 1 Novel
43 33 43 6647 AT D2216V CL 1 Novel
44 34 44 6740 CT S2246L CL 1 Priori (5)
45 35 44 6761 CT A2254V CL 1 Postma (34)
46 45 6800 GA R2267H CL Tester (36)
47 36 45 6886 GC E2296Q FKBP 1 Novel
48 45 6916 GA V2306I FKBP Laitinen (37)
49 45 6919 TC F2307L FKBP Berge (38)
50 46 6933 GA E2311D FKBP Priori (3)
51 46 6992 TC V2321M FKBP Nishio (39)
52 46 6982 CT P2328S FKBP Laitinen (37)
53 46 6992 TC F2331S FKBP Creighton (40)
54 46 7076 GA R2359Q FKBP Aizawa (41)Continued on next page
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November 24, 2009:2065–74 RYR2 Screening in CPVT or Gene Negative LQTSontinuedTable 2 Continued
Patient
#
Mutation
Number
(Fig. 1) Exon Base Position
Amino Acid
Change Location
Cases Hosting
Variant
(n  155)
AA Hosting
Variant
(n  100)
CC Hosting
Variant
(n  100)
First Author
(Ref. #)
55 47 7157 AT N2386I FKBP Tiso (24)
56 37 47 7158 GA A2387T FKBP 3 Tester (14)
57 47 7158 GA A2387P FKBP Bagattin (42)
58 38 47 7165 AC M2389L FKBP 1 Tester (43)
59 47 7175 A5 Y2392C FKBP Bauce (33)
60 47 7181 CG A2394G FKBP Postma (34)
61 39 47 7202 GA R2401H FKBP 1 Aizawa (41)
62 47 7207 GT R2401L FKBP Creighton (40)
63 40 47 7207 GA A2403T FKBP 1 Choi (28)
64 41 47 7210 CA R2404T FKBP 1 Beckman (44)
65 42 48 7258 AT R2420W FKBP 1 Novel
66 49 7422 GC P2474S FKBP Priori (3)
67 49 7423 GT V2475F FKBP Tester (32)
68 49 7511 CT T2504M FKBP Tiso (24)
69 49 Not reported L2487I FKBP Tester (43)
70 50 7528 TC T2510A FKBP Tester (31)
71 50 7599 CG L2534V FKBP Hasdemir (45)
72 43 61 8874 AG Q2958R Cytosol 40 10 36 Tiso (24)
73 69 Not reported N3308S Cytosol Marjamaa (21)
74 75 Not reported R3570W Cytosol Marjamaa (35)
75 83 11332 CT L3778F Cytosol Priori (3)
76 44 83 11399 GT C3800F Cytosol 1 Tester (14)
77 86 11636 TC L3879P Cytosol Tester (31)
78 87 11773 CG Q3925E Cytosol Tester (31)
79 45 88 11814 CA S3938R Cytosol 1 Tester (14)
80 88 11836 GA G3946S Cytosol Priori (3)
81 88 Not reported G3946A Cytosol Davis (30)
82 88 11876 CT S3959L Cytosol Tester (31)
83 46 89 11916 GT M3972I Cytosol 1 Novel
84 47 89 11917 GC D3973H Cytosol 1 Novel
85 48 89 11921 TA L3974Q Cytosol 1 Novel
86 49 90 11989 AG K3997E Cytosol 1 Novel
87 50 90 12028 GA V4010M Cytosol 1 Tester (43)
88 90 Not reported F4020L Cytosol Postma (34)
89 51 90 12226 AG E4076K Cytosol 1 Postma (34)
90 90 12290 AG N4097S Cytosol Tester (46)
91 90 12311 AT N4104I Cytosol Postma (34)
92 90 12312 CG N4104K Cytosol Priori (3)
93 90 Not reported L4105F Cytosol Hasdemir (47)
94 52 90 12322 CA H4108N Cytosol 1 Postma (34)
95 90 Not reported H4108Q Cytosol Postma (34)
96 53 90 12370 AG S4124G Cytosol 1 Novel
97 54 90 12371 GC S4124T Cytosol 1 Tester (14)
98 90 Not reported R4144C Cytosol Berge (38)
99 90 12436 GA E4146K Cytosol Tester (46)
100 55 90 12446 AG Y4149S† Cytosol 1 Novel
101 56 90 12470 GA R4157Q Cytosol 1 Novel
102 90 12472 AC T4158P Cytosol Tester (46)
103 57 90 12476 AG Q4159P Cytosol 1 Novel
104 58 90 12533 AG N4178S Cytosol 3 Novel
105 59 90 12559 GC E4187Q Cytosol 1 Novel
106 60 90 12586 AG T4196A Cytosol 1 Tester (20)
107 90 12601 CA Q4201R Cytosol Laitinen (37)
108 61 90 12845 CT A4282V Cytosol 1 Tester (43)Continued on next page
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RYR2 Screening in CPVT or Gene Negative LQTS November 24, 2009:2065–74ould capture the remaining RYR2-positive cases and
he charge to do so would be $123,225 ($795 per case)
Fig. 5).
iscussion
xertional syncope: LQTS or CPVT? It has been re-
orted that nearly 30% of CPVT cases have been misdiag-
osed as “LQTS with normal QT intervals” or “concealed
QTS” (13). Recently, we demonstrated that nearly 6% of
69 LQTS genotype-negative patients hosted a putative
PVT1-causing RYR2 mutation (14). Here, we included
nly referral cases of “atypical/possible LQTS” with a
henotype of exertional syncope and QTc 480 ms.
ontinuedTable 2 Continued
Patient
#
Mutation
Number
(Fig. 1) Exon Base Position
Amino Acid
Change
109 90 12919 CT R4307C
110 62 90 12944 GA G4315E
111 91 13291 GA E4431K
112 93 13489 CT R4497C
113 63 93 13496 TG F4499C
114 93 13512 GA M4504I
115 64 93 13528 GA A4510T
116 93 Not reported F4511L
117 65 94 13666 GA A4556T
118 94 13695 CA S4565R
119 95 13819 GC A4607P
120 95 13831 GA E4611K
121 96 Not reported W4645R
122 66 96 13948 AG K4650E
123 96 13957 AG V4653F
124 67 97 13967-13972 Dup 4657-4658 ins EY
125 97 Not reported G4662S
126 68 97 14011 GC G4671R
127 69 99 14205-14208 Del N4736 Del
128 99 14285 AC H4762P
129 70 100 14311 GA V4771I
130 71 100 14369 GA R4790Q
131 72 100 14414 AG K4805R
132 73 101 14465 GA R4822H
133 74 101 14542 GA I4848V
134 101 14552 TG F4851C
135 101 14579 CG A4860G
136 102 14601 TG I4867M
137 102 14639 TC V4880A
138 103 14683 AG N4895D
139 103 14705 CT P4902L
140 103 Not reported P4902S
141 104 14806 GA G4936R
142 105 14848 GA E4950K
143 75 105 14876 GA R4959Q
olumn 1 indicates the worldwide compendium of RYR2 variants (mutations and polymorphisms)
28, including 2 large genomic rearrangements involving exon 3, not detectable by regular genet
KBP  12.6 (Calstabin) binding domain; NT  amino-terminal; TMD  transmembrane domain. *
. †Mosaicism.
AA  African-American controls; CC  Caucasian controls.erein, the yield of RYR2 mutations for these 45 cases was a1%, indicating the critical importance of properly distin-
uishing between CPVT and LQTS. CPVT-related ar-
hythmias can be easily reproduced during an exercise stress
est, by isoproterenol infusion, or by other forms of adren-
rgic stimulation (15,16). The induction of polymorphic
entricular tachycardia or bidirectional VT, characterized by
180° alternating QRS axis on a beat-to-beat basis, sets
PVT apart from “concealed” or “borderline” LQTS.
YR2 genetic approach: targeted scan and tiered strategy.
ur results confirm that mutation clustering exists. The
unctional significance of mutation clustering remains un-
lear. It has been suggested, however, that a domain-
omain interaction is crucial for channel function (17–19),
cation
Cases Hosting
Variant
(n  155)
AA Hosting
Variant
(n  100)
CC Hosting
Variant
(n  100)
First Author
(Ref. #)
tosol Callis (48)
tosol 1 Novel
tosol Berge (38)
D Priori (5)
D 1 Choi (28)
D Bagattin (42)
D 2 Choi (28)
D Beckmann (44)
D 1 Tester (14)
D Tester (36)
D Bagattin (42)
D Berge (38)
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November 24, 2009:2065–74 RYR2 Screening in CPVT or Gene Negative LQTSisease phenotypes. Interestingly, in this study, 11 of 64
17%) putative mutations localized outside the considered
anonical domains.
On the basis of our results and after analyzing a large
ublicly available compendium of the 128 RYR2 putative
utations known to date (Table 2), we propose an ex-
Figure 2 RyR2 Channel Topology and Localization of Mutations
Linear topology of the cardiac ryanodine receptor (RyR2); putative pathogenic muta
study cohort are shown in the approximate location. The number within the circle
Figure 3 Prevalence of RYR2 Mutations by Subgroups
The yield from the entire RYR2 scan on this cohort is shown on the left. Bars on
the right show the yield in the 3 different subgroups of this cohort. CPVT  cat-
echolaminergic polymorphic ventricular tachycardia; LQTS  long QT syndrome.canded genetic approach for research/investigational labo-
atories. A reasonable RYR2 scan will include the analysis of
t least 45 exons in total known to host all published
utations reported to date. Since 19 exons imbibed in the
ot-spot region remain free of mutations so far, a more
mbitious and “comprehensive” RYR2 genetic test would
nclude these exons as well, resulting in a 64-exon scan
exons 3 to 28, 37 to 50, 75, and 83 to 105).
The mutation clustering phenomena might facilitate a
iered strategy that may yield a more cost-effective approach
or CPVT genetic testing. Figure 4 summarizes this pro-
osed tiered strategy. The approach was developed consid-
ring the number of mutations in each exon reported to date
n the literature. The first tier comprises those exons (n 
6) now known to host 3 unique CPVT-associated
utations. The second tier includes 13 exons with at least 2
utations reported, and the third tier consists of the final 16
xons where, so far, only a single mutation within that exon
as been reported. Considering that 65% of the RYR2
utation-positive cases might have a mutation in the first
ier of 16 RYR2 exons, the charge of the genetic analysis in
his group could be reduced by approximately one-half
predicted U.S. $1,232 per case for the first tier of 16 exons
s. $3,019 per case for the entire sequencing of exons
Polymorphisms
(yellow circles) and polymorphisms (blue circles) found in this
ponds to the mutation number on Table 2. SR  sarcoplasmic reticulum.and
tions
corresontaining reported mutations).
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omprehensive (64-exon) RYR2 scan mentioned previously
exons 3 to 28, 37 to 50, 75, and 83 to 105) be performed.
dditional “rare” although documented causes of CPVT
hould also be considered, like large RYR2 genomic re-
rrangements involving exon 3 and mutations in calsequestrin
(CASQ2) and Kir2.1 (KCNJ2) (20). The area surrounding
xon 3 is highly susceptible to large Alu-repeat–mediated
enomic rearrangements; we documented 3 unrelated cases
osting large heterozygous deletions involving exon 3 that
ould not be detected by regular genetic screening using
igh-performance liquid chromatography or direct DNA
equencing. Validating this observation, exon 3 deletion was
lso reported recently in a different cohort, in which 2
Figure 4 Possible Tiered Strategy for RYR2 Genetic Testing
Schematic representation of the 105 coding exons of the RYR2 gene. Colored box
sent exons free of reported mutations. The tiered strategy was built on the basis o
first tier included 16 exons; the second tier, 13 exons; and the third tier, 16 exon
Figure 5 Yield From RYR2 Mutational
Analysis on the Basis of a Tiered Strategy
Retrospective analysis of the mutations detected in our cohort (purple bars)
and in the world-wide compendium (orange bars) of mutations reported to
date. The percentage of mutations that would be detected using the tiered
strategy is shown.snrelated cases (of 33) hosted a 1.1kb deletion, including
xon 3 (21).
olymorphisms in RYR2, not that rare and with potential
unctional effect. It has been considered that RYR2 is not
polymorphic gene. However, 15 of 142 (10.5%) missense
ariants reported to date were found in control subjects. We
id not scan the entire RYR2 gene in control subjects.
nstead, because we focused on the exon-containing muta-
ions, the rate of nonsynonymous genetic variation through-
ut all of RYR2 may be higher. Importantly however,
mong the exons now known to host possible CPVT1-
ssociated missense mutations, similarly rare amino acid
ubstitutions were found in only 6 of the 200 control
ubjects (3%) examined in this study. Although not a true
ase-control genetic epidemiologic study, if validated, this
ould suggest that among cases where CPVT is strongly
uspected, there would be a 95% estimated probability that
he identification of a rare missense mutation would likely
epresent the pathogenic basis for the patient’s CPVT,
ather than merely being only a rare amino acid substitution.
We have learned that common polymorphisms in other
on channels have the potential to modify the clinical
henotype (22,23); polymorphisms in RYR2 may have the
ame potential. The most common RYR2 polymorphism is
yR2-Q2958R, described for the first time 9 years ago (24),
nd it is particularly common among Caucasians (34%).
he second most common polymorphism in RYR2 is
1886S (20% African Americans, 9% Caucasians), fol-
owed by G1885E (6% Caucasians). Interestingly, in vitro
tudies in heterologous systems have demonstrated that
oth G1885E and G1886S polymorphisms caused a signif-
cant increase in the cellular Ca(2) oscillation activity
ompared with RyR2 wild-type channels. Further, when
oth polymorphisms were introduced in the same RyR2
resent all of the exon-containing mutations reported to date; white boxes repre-
number of mutations contained in each exon as shown by 3 different colors. The
ns containing control variants were not included.es rep
f the
s. Exoubunit, the store-overload-induced calcium release activity
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November 24, 2009:2065–74 RYR2 Screening in CPVT or Gene Negative LQTSas nearly completely abolished (25). The clinical conse-
uences of this “RyR2 loss of function” in vitro phenotype
s not clear; however, compound heterozygosity involving
hese 2 polymorphisms has been reported in right ventric-
lar dysplasia (26). The potential functional effects of the 6
ovel polymorphisms identified in this study are unknown.
It is important to remark that none of the novel muta-
ions detected in this study have been functionally charac-
erized to further bolster the contention of pathogenicity.
owever, 15% of the mutations reported to date in RYR2
ave been studied in vitro; pathogenicity has been suspected
ased on cosegregation with the disease and absence in
ontrol subjects. Here, cosegregation with the disease data
as not available for all cases. Instead, the prevalence of rare
utations among strong cases (60%) was markedly higher
han in control cases (3%), and all putative mutations were
bsent in 400 reference alleles. Thus, although the precise
ontribution of each discrete mutation to the phenotype
emains to be determined, statistically, the estimated prob-
bility for pathogenicity for RYR2 mutations found in
trong cases is quite high (95%).
osaicism in RYR2. This is the first report involving
YR2 mosaicism that was transmitted to descendants,
resumably causing sudden death in 2 children and full-
lown CPVT in 1 child from the age of 9 years. The RYR2
utations, in many circumstances (20% in our cohort) are
e novo in origin, but they could also be present in a mosaic
orm in the asymptomatic parents, and that requires atten-
ion during genetic counseling as well as during genetic
creening.
linical significance. This study represents the first anal-
sis of RYR2 mutation distribution in a large cohort of
ases. Our results contribute to a better delineation of the
hot spot” regions with important consequences in “gene
egative” definition. The identification of novel common
ariants in control subjects facilitates better interpretation of
he CPVT genetic test. Detection of RYR2 mosaicism, and
onfirmation of exon 3 deletion in different patient-cohorts,
rovides novel genetic possibilities for the pathogenesis of
PVT. Moreover, the development of a tiered strategy for
YR2 genetic scan may enable a more cost-effective genetic
pproach to analyzing one of the largest genes in the human
enome. Finally, we emphasize the critical importance of
roperly distinguishing between CPVT and LQTS (includ-
ng Andersen-Tawil syndrome), 2 different diseases with a
imilar clinical presentation but different clinical outcomes
nd different responsiveness to pharmacotherapy.
onclusions
lthough intimidating, as one of the largest genes in the
uman genome, results from this comprehensive open
eading frame analysis involving one of the largest cohorts of
nrelated patients examined, combined with a detailed
nalysis of all published CPVT1-associated mutations indi-
ate that to date, only 45 of RYR2’s 105 translated exons
1ost a putative CPVT1-associated mutation thus far. More-
ver, an initial targeting of only 16 exons would allow the
dentification of putative mutations in 65% of the RYR2-
utation positive cases, although compound heterozygosity
ay be missed. Finally, given the present estimate of 3%
requency for rare missense mutations among controls, one
ust be cognizant of the possibility of a “false positive”
specially as the pre-test probability of a CPVT diagnosis
ecreases. The 33% yield that was observed among the
possible” cases of CPVT indicates that perhaps 90% of the
utations, identified among cases labeled as “possible
PVT” or so-called “atypical LQTS” with exercise-induced
yncope and QTc480 ms, are pathogenic, whereas 10% of
hose mutations may represent false positives.
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APPENDIX
or a supplementary table listing conservation across species
f the novel RYR2 variants, please see the online version of this article.
